BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 28154266)

  • 1. The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.
    Shimomura Y; Takaki A; Wada N; Yasunaka T; Ikeda F; Maruyama T; Tamaki N; Uchida D; Onishi H; Kuwaki K; Nakamura S; Nouso K; Miyake Y; Koike K; Tomofuji T; Morita M; Yamamoto K; Okada H
    Intern Med; 2017; 56(3):243-251. PubMed ID: 28154266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
    Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
    PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
    Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
    Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Levels of Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Steatohepatitis.
    Casoinic F; Sampelean D; Buzoianu AD; Hancu N; Baston D
    Rom J Intern Med; 2016 Dec; 54(4):228-236. PubMed ID: 28002036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
    Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
    BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
    Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
    Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
    Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.
    Enooku K; Nakagawa H; Fujiwara N; Kondo M; Minami T; Hoshida Y; Shibahara J; Tateishi R; Koike K
    Sci Rep; 2019 Jul; 9(1):10663. PubMed ID: 31337855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.